GlassScriptPhysician profile
Gretchen Korver
NPI 1164456414
$8,335.97
in general payments reported to CMS, 2019-2025
32 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $782 · 2021: $635 · 2022: $1,380 · 2023: $1,412 · 2024: $1,917 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,573 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.52 |
| Education | $228.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,897.26 | 2019-2025 | |
| Lilly USA, LLC | $718.08 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Sun Pharmaceutical Industries INC. | $708.88 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $631.51 | 2019-2025 | Otezla |
| Incyte Corporation | $557.61 | 2021-2025 | Opzelura |
| Ucb, INC. | $542.61 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $452.27 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $432.85 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $323.84 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $280.62 | 2019-2025 | |
| Genzyme Corporation | $246.38 | 2019-2025 | |
| Allergan, INC. | $228.87 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $177.79 | 2020-2023 | Jublia |
| Pfizer INC. | $144.85 | 2019-2024 | |
| Dermavant Sciences, INC. | $137.60 | 2023 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $108.45 | 2025 | Nemluvio |
| Biofrontera INC. | $101.23 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $94.49 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $92.01 | 2019 | |
| Arcutis Biotherapeutics, INC. | $81.06 | 2024-2025 | Zoryve |
| Merz North America, INC. | $76.01 | 2019-2022 | |
| Dermira, INC. | $68.33 | 2020 | |
| Vyne Pharmaceuticals INC. | $42.50 | 2020 | |
| Prugen, INC. Pharmaceuticals | $36.44 | 2019-2020 | |
| Organogenesis INC. | $27.13 | 2019 | |
| Krystal Biotech INC | $23.60 | 2023 | Vyjuvek |
| Botanix Sb INC | $22.82 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $22.00 | 2023 | Ycanth |
| Mayne Pharma Commercial LLC | $19.71 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.46 | 2025 | Valchlor |
| Pierre Fabre Pharmaceuticals, INC. | $12.77 | 2019 | |
| Organon LLC | $7.94 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Korver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.